Abstract
Antileukotriene agents are one of the most recent additions to the therapeutic arsenal for asthma. They are very specific in their activity, blocking the action of leukotrienes. However, since these actions can result in multiple adverse effects, antileukotriene agents have the potential to deal with many aspects of the disease, including smooth muscle proliferation, airway hyperactivity, smooth muscle contraction, and eosinophil influx. Antileukotriene agents are indicated for the therapy of asthma from mild persistent to severe.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Reading
Barnes N, Wei LX, Reiss TF, et al. Analysis of montelukast in mild persistent asthmatic patients with nearnormal lung function. Respir Med 2001;95(1):379–386.
Baumgartner RA, Martinez G, Edelman JM, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J 2003;21(1):123–128.
Bisgaard H, Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003;167(3):379–383.
Busse W, Raphael G, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001;107(3):461–468.
Camargo CA, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003;167:528–533.
Edelman JM. Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid. 12th European Respiratory Society Annual Congress, Sept. 14–28, 2002, Stockholm, Sweden, 2002:P771.
GINA. Global Initiative for Asthma. Global strategy for asthma management and prevention. US Department of Health and Human Services, February 2002. NIH Publication No. 02-3659.
Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002;110(6):847–854.
Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-to 14-year old patients with asthma. J Pediatr 1998;133(3):424–428.
Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6-to 14-year-old children. A randomized, double-blind trial. JAMA 1998;279(15):1181–1186.
Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862–1868.
Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339(3):147–152.
Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6 month randomized multicenter trial. J Allergy Clin Immunol 1996:98;859–871.
Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319(7202):87–90.
Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 1999;130(6):487–495.
Meltzer EO, Lockey RF, Friedman BF, et al. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin Proc 2003;77(5):437–445.
NAEPP. National Asthma Education and Prevention Program: Guidelines for the Diagnosis and Management of Asthma. Update on Selected Topics 2002. J Allergy Clin Immunol 2002;110(5):S1–S219.
Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998;102:935–942.
Persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108(3):e48.
Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211–216.
Price DB, Rouleau MY, Fletcher CP, et al. Use of montelukast in tapering inhaled corticosteroid therapy: An open-label 48-week trial. Curr Ther Res 2001;62(11):743–755.
Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998;158(11):1213–1220.
Sensitive asthmatics to aspirin. Am Rev Respir Dig 1999;148:1447–1451.
Spector SL. Leukotriene activity modulation in asthma. Drugs 1997;54(3);369–384.
Spector SL, Smith LI, Glass M. “Accolate” Asthma Trialist Group. Effects of 6 weeks of therapy with oral doses of ICI-204.219, a leukotriene D receptor antagonist in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618–623.
The Childhood Asthma Management Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343(15):1054–1063.
Vaquerizo MJ, Casen P, Castillo J, et al. Montelukast added to patients incompletely controlled on inhaled budesonide. Am J Respir Crit Care Med 2001;163(5):A430.
Virchow J, Hassall SM, Summerton L. Harris A. Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high-dose inhaled corticosteroids. J Invest Med 1997;45:286A.
Zeiger RS. Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid. 12th European Respiratory Society Annual Congress, Sept. 14–28, 2002, Stockholm, Sweden, 2002:1.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press, Totowa, NJ
About this chapter
Cite this chapter
Spector, S.L. (2007). Antileukotriene Agents in the Management of Asthma. In: Lieberman, P., Anderson, J.A. (eds) Allergic Diseases. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-382-0_20
Download citation
DOI: https://doi.org/10.1007/978-1-59745-382-0_20
Publisher Name: Humana Press
Print ISBN: 978-1-58829-603-0
Online ISBN: 978-1-59745-382-0
eBook Packages: MedicineMedicine (R0)